You are viewing: US Latent TB Testing Market analysis
Part of: Latent TB Testing Market (Global)

The US Latent TB Testing Market was valued at $163.12 Million in 2024 and projected to reach to $189.58 Million by 2029, representing a compound annual growth rate of 3.1%. The US latent TB testing market is positioned for steady growth through 2029, supported by increasing awareness of tuberculosis screening importance in clinical practice and occupational health settings.

US Latent TB Testing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Latent TB Testing Market Trends and Insights

  • The US market is driven by increasing awareness of tuberculosis screening in healthcare settings, rising adoption of interferon-gamma release assays (IGRAs), and strengthened public health initiatives targeting high-risk populations.
  • In 2024, the US established itself as a mature market with established diagnostic infrastructure and regulatory frameworks supporting latent TB detection. Growth in the US latent TB testing market through 2029 is supported by expanded screening programs in occupational health, immigration medical examinations, and healthcare worker protocols.
  • The US continues to invest in point-of-care testing solutions and digital health integration to improve accessibility and turnaround times.
  • By 2029, the US market is expected to benefit from technological advancements in rapid testing methodologies and increased reimbursement coverage, positioning the country as a key driver of innovation in latent TB diagnostics within North America..

Key Market Statistics

  • CAGR (2024-2029) 3.1% CAGR
  • Market Size, 2024 ~USD 163.12 Million
  • Forecast, 2029 ~USD 189.58 Million
  • Country US

US Latent TB Testing Market Overview

Market Valuation :

The US latent TB testing market reached $163.12 million in 2024, with projected growth to $189.58 million by 2029, representing a steady 3.1% CAGR driven by enhanced screening protocols.

IGRA Adoption Growth :

Interferon-gamma release assays (IGRAs) are experiencing increased adoption across US healthcare facilities due to superior specificity compared to tuberculin skin tests and reduced cross-reactivity with BCG vaccination.

Public Health Initiatives :

Strengthened CDC-led TB elimination programs and targeted screening in high-risk populations including healthcare workers, immigrants, and immunocompromised individuals are accelerating market expansion across US regions.

Healthcare Setting Integration :

Growing integration of latent TB testing into routine occupational health screenings and pre-employment medical evaluations in US hospitals and clinics is driving consistent market demand.

US Latent TB Testing Market Dynamics

  • Healthcare providers are progressively shifting toward more accurate diagnostic methods, particularly IGRAs, which offer improved sensitivity and specificity.
  • Regulatory support from public health agencies and mandatory screening requirements in healthcare facilities continue to strengthen market fundamentals.
  • The market's 3.1% CAGR reflects a mature but expanding segment driven by clinical best practices and preventive healthcare trends.
  • Continued investment in TB elimination initiatives and enhanced screening protocols across US healthcare systems will sustain demand for latent TB testing solutions through the forecast period..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • CONMED Corporation

    Key Takeaways

    • The US latent TB testing market reached $163.12 million in 2024 with a projected value of $189.58 million by 2029, reflecting steady 3.1% CAGR growth.
    • The US market is characterized by mature diagnostic infrastructure, established regulatory pathways, and widespread adoption of IGRAs as the preferred testing modality.
    • Growth in the US is driven by occupational health screening, immigration medical requirements, and healthcare worker protocols that mandate latent TB testing.
    • The US market is expected to see innovation in rapid testing technologies and expanded reimbursement coverage by 2029, enhancing market accessibility and adoption rates.

    Latent TB Testing Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment HOUSEHOLD CONTACTS WITH PULMONARY TB (Application)
    Forecast Period 2024-2029
    Growth Rate CAGR of 5.8% from 2024 to 2029
    Largest Segment IGRA (Test Type)
    Market Size Base Year (Billions) ~USD 0.58 (2024)
    Revenue Forecast (Billions) ~USD 0.77 (2029)
    Segments Covered Test Type, Application, End User

    US Latent TB Testing Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Test Type

    • Igra
    • Tst

    By Application

    • Household Contacts With Pulmonary Tb
    • Other Applications
    • People Living With Hiv

    By End User

    • Academic & Research Institutes
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Other End Users

    US: LATENT TB TESTING MARKET, BY END USER, 2022–2029

    Segment20222023202420252026202720282029CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES10.3311.6311.6111.6611.8212.0512.3612.711.8
    DIAGNOSTIC LABORATORIES113.6129.63131.04133.39136.99141.49146.96153.13.2
    HOSPITALS & CLINICS33.5537.9838.0938.4639.1840.1541.3742.762.3
    OTHER END USERS5.376.025.985.976.036.116.246.381.3
    TOTAL162.86185.26186.71189.49194.02199.8206.91214.942.9

    Target Audience

    • Diagnostic Device Manufacturers : Need US-specific market data to evaluate market entry opportunities, assess competitive positioning, forecast revenue potential, and develop localized marketing strategies for IGRA and TB testing platforms.
    • Healthcare Facility Administrators : Require market insights to justify TB screening program investments, benchmark testing volumes against national trends, optimize occupational health protocols, and allocate budgets for diagnostic testing infrastructure.
    • Clinical Laboratory Directors : Seek detailed market analysis to understand testing demand trends, evaluate technology upgrades from TST to IGRA methods, plan capacity expansion, and identify growth opportunities in TB screening services.
    • Public Health & Government Agencies : Need comprehensive US market data to inform TB elimination policy decisions, allocate public health resources, evaluate screening program effectiveness, and track progress toward national TB control objectives.
    • Investment & Consulting Firms : Require validated US market forecasts and growth metrics to support due diligence, portfolio analysis, M&A evaluations, and strategic recommendations for healthcare diagnostics and public health sector clients.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise US market valuation ($163.12M in 2024) and verified forecast data through 2029 to support strategic planning, investment decisions, and competitive positioning in the latent TB testing segment.
    • Regional Performance Insights : Access detailed analysis specific to the US market dynamics, including CAGR trends, adoption patterns, and regional variations that differ from global market performance, enabling targeted business strategies.
    • Technology & Method Adoption Trends : Understand the shift toward IGRA methodologies in US healthcare settings, including adoption rates, clinical integration patterns, and competitive advantages that inform product development and market entry strategies.
    • Regulatory & Policy Landscape : Gain insights into US-specific public health initiatives, CDC guidelines, occupational health requirements, and screening mandates that directly influence market demand and growth opportunities.
    • Competitive Benchmarking : Leverage US-focused market data to benchmark performance against competitors, identify market gaps, assess pricing strategies, and develop targeted go-to-market approaches for healthcare providers and diagnostic companies.

    Frequently asked questions

    What is the current size of the US latent TB testing market?

    The US latent TB testing market was valued at $163.12 million in 2024 and is expected to reach $189.58 million by 2029.

    What is the growth rate of the US latent TB testing market?

    The US latent TB testing market is growing at a compound annual growth rate (CAGR) of 3.1% from 2024 to 2029.

    What are the primary drivers of growth in the US latent TB testing market?

    Key drivers include occupational health screening requirements, immigration medical examinations, healthcare worker protocols, and increased adoption of interferon-gamma release assays (IGRAs).

    Which testing modalities dominate the US latent TB testing market?

    Interferon-gamma release assays (IGRAs) are the preferred testing modality in the US, offering advantages over tuberculin skin tests in terms of specificity and ease of administration.

    What innovations are expected in the US latent TB testing market by 2029?

    Expected innovations include point-of-care testing solutions, digital health integration, rapid testing methodologies, and expanded reimbursement coverage to improve accessibility and diagnostic efficiency.

    RESEARCH METHODOLOGY

    The study involved major activities in estimating the current market size for the latent TB testing market. Exhaustive secondary research was done to collect information on the latent TB testing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the latent TB testing market.

    The four steps involved in estimating the market size are

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

    The following is a breakdown of the primary respondents:

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    COMPANY NAME DESIGNATION
    QIAGEN General Manager
    Revvity Area Sales Manager

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the latent TB testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • The revenues generated by leading players operating in the latent TB testing market have been determined through primary and secondary research.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    The research methodology used to estimate the market size includes the following:

    Data Triangulation

    After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Latent tuberculosis testing refers to diagnosing the infection by detecting an immune response to Mycobacterium tuberculosis antigens using either the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). These tests help identify dormant tuberculosis infections in individuals without active symptoms.

    Stakeholders

    • Senior Management
    • End User
    • Finance/Procurement Department  
    • R&D Department

    Report Objectives

    • To define, describe, segment, and forecast the global latent TB testing market, by test type, application, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall latent TB testing market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
    • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

     

    Get the Full Latent TB Testing Market Report

    Full forecast, segment splits, and company analysis for all Latent TB Testing Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status